In September 2026, CITEST Diagnostics Inc. has officially launched its West Nile Virus IgG/IgM Rapid Tests, a professional in-vitro diagnostic assay developed to identify WNV-specific IgG and IgM antibodies within human whole blood, serum and plasma samples. Built upon lateral-flow immunochromatography technology, this assay enables simultaneous dual-antibody detection. It helps clinicians screen suspected West Nile Virus infections and provides supportive laboratory evidence for case confirmation. Definite test results can be obtained within 15 minutes, and no sophisticated lab apparatus is needed.
Engineered for convenient professional pathogen screening workflows, the West Nile Virus IgG/IgM Rapid Tests feature multiple outstanding strengths. It achieves high detection accuracy. The assay supports simultaneous IgG and IgM antibody testing. Trustworthy readouts are ready in 15 minutes. The procedure is straightforward and test bands can be interpreted visually with ease. Additionally, the kit offers flexible compatibility with different sample matrix types.
Made for reliable West Nile Virus serological screening, this rapid test accepts whole blood, serum or plasma as test specimens and only requires basic operational proficiency from lab personnel. This product comes in cassette format with catalogue number RTWNVCI. Each box contains 25 test units (25T). This product is restricted to professional in-vitro diagnostic applications only.
West Nile Virus (WNV) is a mosquito-borne neurotropic pathogen capable of triggering West Nile fever and life-threatening severe encephalitis. This virus is endemic across Africa, Europe, the Middle East, North America and West Asia. It circulates naturally between avian reservoir hosts and mosquito vectors. Most infected people remain asymptomatic, while roughly 20% develop fever, headache and malaise. The elderly and immunocompromised groups face substantially higher risks of severe disease complications.
The West Nile Virus IgG/IgM Rapid Tests addresses clinical needs for rapid point-of-care WNV screening. With dual-antibody detection, fast turnaround and simple visual interpretation, this newly released assay reinforces CITEST Diagnostics Inc.’s reputation as a trusted provider of rapid diagnostic solutions, delivering consistent performance to assist medical institutions in identifying suspected West Nile Virus infections.
